| Literature DB >> 32485527 |
Giandomenico Roviello1, Sara Fancelli2, Marta Rita Gatta Michelet2, Giuseppe Aprile3, Stefania Nobili4, Franco Roviello5, Fabio Cianchi6, Enrico Mini4, Daniele Lavacchi2.
Abstract
TAS-102 is a preconstituted drug combination comprising an oral fluoropyrimidine (trifluridine, TFT) and a potent inhibitor of thymidine phosphorylase (tipiracil hydrochloride, TPI). TFT/TPI has recently received Food and Drug Administration (FDA) approval also for the treatment of gastric cancer after at least two lines of chemotherapy. The approval was based on a large phase 3 trial (TAGS), in which TAS-102 showed a 31 % decrease in the risk of death compared with placebo. Here, we review the pharmacological properties, clinical development and potential future directions of TAS-102 in gastric cancer.Entities:
Keywords: Chemotherapy; Gastric cancer; TAS-102; Third line
Year: 2020 PMID： 32485527 DOI： 10.1016/j.critrevonc.2020.102987
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312